Neurosense Therapeutics Cash Per Share vs. Total Debt
| NRSN Stock | USD 0.93 0.03 3.33% |
Cash Per Share | First Reported 2010-12-31 | Previous Quarter 0.19354839 | Current Value 0.18 | Quarterly Volatility 1.366106 |
For Neurosense Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Neurosense Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Neurosense Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Neurosense Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Neurosense Therapeutics over time as well as its relative position and ranking within its peers.
Neurosense |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Return On Assets (1.51) | Return On Equity (4.95) |
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Neurosense Therapeutics Total Debt vs. Cash Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Neurosense Therapeutics's current stock value. Our valuation model uses many indicators to compare Neurosense Therapeutics value to that of its competitors to determine the firm's financial worth. Neurosense Therapeutics is rated below average in cash per share category among its peers. It is rated below average in total debt category among its peers making up about 159,551 of Total Debt per Cash Per Share. At this time, Neurosense Therapeutics' Cash Per Share is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neurosense Therapeutics' earnings, one of the primary drivers of an investment's value.Neurosense Total Debt vs. Cash Per Share
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Neurosense Therapeutics |
| = | 0.89 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Neurosense Therapeutics |
| = | 142 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Neurosense Total Debt vs Competition
Neurosense Therapeutics is rated below average in total debt category among its peers. Total debt of Health Care industry is now estimated at about 25.11 Million. Neurosense Therapeutics maintains roughly 142,000 in total debt contributing less than 1% to equities under Health Care industry.
Neurosense Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Neurosense Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Neurosense Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Neurosense Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Neurosense Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 30.2 M | 18 M | |
| Net Interest Income | -372 K | -390.6 K | |
| Interest Income | 178 K | 186.9 K | |
| Operating Income | -12 M | -11.4 M | |
| Net Loss | -11.3 M | -10.7 M | |
| Income Before Tax | -11.3 M | -10.7 M | |
| Total Other Income Expense Net | 769 K | 792 K | |
| Net Loss | -3.6 M | -3.8 M | |
| Net Loss | -11.3 M | -10.7 M | |
| Income Tax Expense | (1.00) | (1.05) | |
| Change To Netincome | 2.6 M | 1.8 M | |
| Net Loss | (0.74) | (0.78) | |
| Income Quality | 0.75 | 0.39 | |
| Net Income Per E B T | 0.90 | 0.98 |
Neurosense Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Neurosense Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Neurosense Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Neurosense Therapeutics' important profitability drivers and their relationship over time.
Use Neurosense Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurosense Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurosense Therapeutics will appreciate offsetting losses from the drop in the long position's value.Neurosense Therapeutics Pair Trading
Neurosense Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Neurosense Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurosense Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurosense Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurosense Therapeutics to buy it.
The correlation of Neurosense Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurosense Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurosense Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurosense Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Neurosense Therapeutics position
In addition to having Neurosense Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Measuring and Control Equipment Thematic Idea Now
Measuring and Control Equipment
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Measuring and Control Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Measuring and Control Equipment Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
To fully project Neurosense Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Neurosense Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Neurosense Therapeutics' income statement, its balance sheet, and the statement of cash flows.